Bill113th Congress

S. 908

Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013

Ask AI
Introduced
May 8, 2013
Origin Chamber
Senate
Policy Area
Health
Latest Action
May 8, 2013

Sponsor

Sen. Johnson, Tim [D-SD]

Democrat·SD
Bioguide ID: J000177
First Name: TIM
Last Name: JOHNSON
By Request: N
6
Cosponsors
1
Committees
2
Actions
0
Amendments
1
Related Bills
11
Subjects
1
Summaries
3
Titles
1
Text Versions

Bill Details

Update Date
Jan 11, 2023
Origin Chamber
Senate
Bill Type
S
Bill Number
908
Congress
113
Introduced Date
May 8, 2013
Policy Area
Health
Is Law
No
May 8, 2013IntroReferral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Source: Senate

May 8, 2013IntroReferral10000

Introduced in Senate

Source: Library of Congress

Introduced in Senate· May 8, 20130

Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a vascular genetic bleeding disorder that causes abnormalities of the blood vessels) initiative to assist in coordinating activities to improve early detection, screening, and treatment of people who suffer from HHT, focusing on advancing research on the causes, diagnosis, and treatment of HHT and increasing physician and public awareness of HHT.

Directs the Secretary to establish the HHT Coordinating Committee to develop and coordinate implementation of a plan to advance research and understanding of HHT, including by: (1) conducting or supporting research across relevant National Institutes of Health (NIH) institutes, and (2) conducting evaluations and making recommendations regarding the prioritization and award of NIH research grants relating to HHT.

Requires the Director of the Centers for Disease Control and Prevention (CDC) to carry out activities with respect to HHT, including conducting population screening and establishing an HHT resource center to provide comprehensive education on, and disseminate information about, HHT to health professionals, patients, industry, and the public. Sets forth requirements for HHT population screening, including requiring the Director of CDC to designate and provide funding for HHT Treatment Centers of Excellence.

Requires the Administrator of the Centers for Medicare & Medicaid Services (CMS) to award grants for: (1) an analysis of the Medicare Provider Analysis and Review (MEDPAR) file to develop preliminary estimates for preventable costs of annual health care expenditures associated with untreated HHT and socioeconomic costs associated with preventable medical events among Medicare beneficiaries with HHT; and (2) recommendations regarding an enhanced data collection protocol to permit a more precise determination of such costs.

Health, Education, Labor, and Pensions Committee

Senate· Standing
Advisory bodiesCardiovascular and respiratory healthHealth care costs and insuranceHealth facilities and institutionsHealth information and medical recordsHealth programs administration and fundingHereditary and development disordersMedical researchMedical tests and diagnostic methodsMedicareResearch administration and funding

Introduced in Senate

May 8, 2013

Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013 — Informed